The study examined the effectiveness of various interventions aimed at increasing lung cancer screening uptake rates.
Lung Cancer
Advertisement
The forum covered critical updates in the fields of NSCLC, SCLC, immunotherapy effectiveness, and recent trial updates.
Dr. Osarogiagbon shared insights on findings from the incidental lung nodule program and lung cancer screening program.
Amivantamab plus lazertinib showed a statistically significant improvement in OS compared with osimertinib.
The study, which expanded on phase 3 ADAURA, compared treatment with neoadjuvant osimertinib with or without chemotherapy.
Results demonstrated extended median progression-free survival by nearly 9 months versus standard of care.
The updated data showed an overall survival benefit with osimertinib for treating EGFR-mutated NSCLC.
The trial compared the combination with chemotherapy alone in patients with EGFR exon 20 insertion-mutated advanced NSCLC.
Jorge Nieva, MD, discusses a recent study that evaluated the impact of circadian rhythms on the efficacy of immunotherapy.
Coral Olazagasti, MD, reflects on ASCO 2025 updates and the importance of bringing this news back to patients in the clinic.
Cheryl Czerlanis, MD, shares insights from her ASCO 2025 presentation on the topic.
The study participants include those who have had at least one first-degree relative diagnosed with lung cancer.
The organization also granted priority review, breakthrough designation, and orphan drug designation to the application.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.